Physician profile
Ronald E Gurney
NPI 1710959192
$2,668.63
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $234 · 2020: $336 · 2021: $488 · 2022: $1,025 · 2023: $556 · 2024: $29.41.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $572 · Education: $13.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $571.80 |
| Education | $13.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $607.61 | 2020-2023 | Xifaxan, Plenvu |
| Abbvie INC. | $374.94 | 2021-2023 | |
| Celgene Corporation | $263.68 | 2022-2023 | Zeposia |
| Novo Nordisk INC | $256.44 | 2020-2023 | Rybelsus, Ozempic, Wegovy |
| E.R. Squibb & Sons, L.L.C. | $199.85 | 2022 | |
| Boston Scientific Corporation | $147.49 | 2023 | Exalt Model D |
| Qol Medical, LLC | $116.87 | 2021-2022 | |
| Olympus America INC. | $112.77 | 2019 | |
| Esperion Therapeutics, INC. | $109.83 | 2020-2021 | |
| Allergan, INC. | $96.94 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $49.68 | 2020-2021 | |
| Alfasigma USA, INC. | $44.45 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.58 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $29.59 | 2020-2021 | |
| Aytu Biopharma, INC. | $29.20 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $24.01 | 2020 | |
| Braintree Laboratories, INC. | $22.07 | 2020 | |
| Pfizer INC. | $17.77 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.79 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $16.38 | 2020 | |
| Exact Sciences Corporation | $16.01 | 2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $15.75 | 2019 | |
| Nestle Healthcare Nutrition INC. | $14.88 | 2022 | |
| Janssen Biotech, INC. | $14.77 | 2022 | |
| Neurelis, INC. | $13.40 | 2024 | Valtoco |
| Horizon Therapeutics Plc | $12.86 | 2021 | |
| Lilly USA, LLC | $12.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Gurney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.